TG Therapeutics to Host Conference Call on Third Quarter 2023 Financial Results and Business Update

Rhea-AI Summary

TG Therapeutics, Inc. (NASDAQ: TGTX) will hold a conference call on November 1, 2023, at 8:30 AM ET to discuss third quarter 2023 results and provide a business outlook. Michael S. Weiss, Chairman and CEO, will host the call. Participants can join by calling 1-877-407-8029 (U.S.) or 1-201-689-8029 (outside the U.S.) with the conference title 'TG Therapeutics'. A live webcast will be available on the company's website, and an audio recording will be accessible for 30 days after the call.

Conference call to be held Wednesday, November 1, 2023, at 8:30 AM ET

NEW YORK, Oct. 30, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held on Wednesday, November 1, 2023, at 8:30 AM ET to discuss results for the third quarter 2023 and provide a business outlook for remainder of the year. Michael S. Weiss, Chairman and Chief Executive Officer of TG Therapeutics, will host the call.

In order to participate in the conference call, please call 1-877-407-8029 (U.S.), 1-201-689-8029 (outside the U.S.), Conference Title: TG Therapeutics. A live webcast of this presentation will be available on the Events page, located within the Investors & Media section, of the Company's website at www.tgtherapeutics.com. An audio recording of the conference call will also be available for replay at www.tgtherapeutics.com, for a period of 30 days after the call.

TG Therapeutics will announce its financial results for this period in a press release to be issued prior to the call.

ABOUT TG THERAPEUTICS
TG Therapeutics is a fully integrated, commercial stage, biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline including several investigational medicines, TG has received U.S. Food and Drug Administration (FDA) approval for BRIUMVI® (ublituximab-xiiy), for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease as well as European Commission (EC) approval for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features. For more information, visit www.tgtherapeutics.com, and follow us on Twitter @TGTherapeutics and on LinkedIn.

CONTACT:
Investor Relations
Email: ir@tgtxinc.com
Telephone: 1.877.575.TGTX (8489), Option 4

Media Relations:
Email: media@tgtxinc.com
Telephone: 1.877.575.TGTX (8489), Option 6

FAQ

When will TG Therapeutics hold its conference call?

TG Therapeutics will hold its conference call on Wednesday, November 1, 2023, at 8:30 AM ET.

Who will host the conference call?

Michael S. Weiss, Chairman and Chief Executive Officer of TG Therapeutics, will host the call.

How can I participate in the conference call?

To participate, please call 1-877-407-8029 (U.S.) or 1-201-689-8029 (outside the U.S.) with the conference title 'TG Therapeutics'.

Where can I find a live webcast of the presentation?

A live webcast of the presentation will be available on the Events page of TG Therapeutics' website at www.tgtherapeutics.com.

Will there be a recording of the conference call?

Yes, an audio recording of the conference call will be available for replay at www.tgtherapeutics.com for a period of 30 days after the call.

When will TG Therapeutics announce its financial results?

TG Therapeutics will announce its financial results for the third quarter 2023 in a press release to be issued prior to the conference call.